ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Michel ML, Tiollais P, 2010. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol (Paris) 58: 288–295.
-
2.
Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L, 2012. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol 4: 74–80.
-
3.
Zanetti AR, Van Damme P, Shouval D, 2008. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26: 6266–6273.
-
4.
Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, Gorecki M, Gerlich WH, 1994. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12: 1453–1459.
-
5.
Martins RM, Bensabath G, Arraes LC, Oliveira MLA, Miguel JC, Barbosa GG, Camacho LAB, 2004. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz 99: 865–871.
-
6.
Moraes JC, Luna EJA, Grimaldi RA, 2010. Imunogenicidade da vacina brasileira contra hepatite B em adultos. Rev Saude Publica 44: 353–359.
-
7.
Ministério da Saúde Brasil, 2015. Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis. Departamento de DST, Aids e Hepatites Virais, ed. Brasília (Brasil): Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais, 120.
-
8.
Souto FJD, 2016. Distribution of hepatitis B infection in Brazil: the epidemiological situation at the beginning of the 21st century. Rev Soc Bras Med Trop 49: 11–23.
-
9.
Ximenes RAA, Figueiredo GM, Cardoso MRA, Stein AT, Moreira RC, Coral G, Crespo D, Santos AA, Montarroyos UR, Braga MC, Pereira LMMB, 2015. Population-based multicentric survey of hepatitis B infection and risk factors in the north, south, and southeast regions of Brazil, 10–20 years after the beginning of vaccination. Am J Trop Med Hyg 93: 1341–1348.
-
10.
Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH, 2013. High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol 58: 262–264.
-
11.
Chathuranga LS, Noordeen F, Abeykoon AM, 2013. Immune response to hepatitis B vaccine in a group of health care workers in Sri Lanka. Int J Infect Dis 17: 1078–1079.
-
12.
Motta-Castro ARC, Gomes SA, Yoshida CFT, Miguel JC, Teles SA, Martins RMB, 2009. Compliance with and response to hepatitis B vaccination in remaining quilombo communities in central Brazil. Cad Saude Publica 25: 738–742.
-
13.
Klein SL, Marriott I, Fish EN, 2015. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg 109: 9–15.
-
14.
Gilbert CL, Klopfer SO, Martin JC, Schödel FP, Bhuyan PK, 2011. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years. Hum Vaccin 7: 1336–1342.
-
15.
Kulkarni PS, Raut SK, Patki PS, Phadke MA, Jadhav SS, Kapre SV, Dhorje SP, Godse SR, 2006. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults. Vaccine 24: 3457–3460.
-
16.
Meeren OVD, Crasta P, Cheuvart B, Ridder MD, 2015. Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: an integrated analysis. Hum Vaccin Immunother 11: 1726–1729.
-
17.
Rosenberg C, Bovin NV, Bram LV, Flyvbjerg E, Erlandsen M, Vorup-Jensen T, Petersen E, 2013. Age is an important determinant in humoral and T cell responses to immunization with hepatitis B surface antigen. Hum Vaccin Immunother 9: 1466–1476.
-
18.
Vijayakumar V, Hari R, Parthiban R, Mehta J, Thyagarajan SP, 2004. Evaluation of immunogenicity and safety of Genevac B: a new recombinant hepatitis b vaccine in comparison with Engerix B and Shanvac B in healthy adults. Indian J Med Microbiol 22: 34–38.
-
19.
Ministério da Saúde Brasil, 2015. Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis. Departamento de DST, Aids e Hepatites Virais, ed. Brasília (Brasil): Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais, 120.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 272 | 237 | 11 |
| Full Text Views | 466 | 9 | 0 |
| PDF Downloads | 151 | 6 | 0 |
Low Immunogenicity of Recombinant Hepatitis B Vaccine Derived from Hansenula polymorpha in Adults Aged Over 40 Years
Karlla Antonieta Amorim Caetano
Karlla Antonieta Amorim Caetano
Nursing School, Federal University of Goias, Goiania, Brazil.
Search for other papers by Karlla Antonieta Amorim Caetano in
Current site
Google Scholar
PubMed
Search for other papers by Karlla Antonieta Amorim Caetano in
Current site
Google Scholar
PubMed
Nativa Helena Alves Del-Rios
Nativa Helena Alves Del-Rios
Institute of Tropical Pathology and Public Health, Federal University of Goias, Goiania, Brazil.
Search for other papers by Nativa Helena Alves Del-Rios in
Current site
Google Scholar
PubMed
Search for other papers by Nativa Helena Alves Del-Rios in
Current site
Google Scholar
PubMed
Raquel Silva Pinheiro
Raquel Silva Pinheiro
Nursing School, Federal University of Goias, Goiania, Brazil.
Search for other papers by Raquel Silva Pinheiro in
Current site
Google Scholar
PubMed
Search for other papers by Raquel Silva Pinheiro in
Current site
Google Scholar
PubMed
Fabiana Perez Rodrigues Bergamaschi
Fabiana Perez Rodrigues Bergamaschi
Nursing School, State University of Mato Grosso do Sul, Dourados, Brazil.
Search for other papers by Fabiana Perez Rodrigues Bergamaschi in
Current site
Google Scholar
PubMed
Search for other papers by Fabiana Perez Rodrigues Bergamaschi in
Current site
Google Scholar
PubMed
Megmar Aparecida dos Santos Carneiro
Megmar Aparecida dos Santos Carneiro
Institute of Tropical Pathology and Public Health, Federal University of Goias, Goiania, Brazil.
Search for other papers by Megmar Aparecida dos Santos Carneiro in
Current site
Google Scholar
PubMed
Search for other papers by Megmar Aparecida dos Santos Carneiro in
Current site
Google Scholar
PubMed
Sheila Araujo Teles
Sheila Araujo Teles
Nursing School, Federal University of Goias, Goiania, Brazil.
Search for other papers by Sheila Araujo Teles in
Current site
Google Scholar
PubMed
Search for other papers by Sheila Araujo Teles in
Current site
Google Scholar
PubMed
The Brazilian recombinant hepatitis B vaccine (VrHB-IB) is based on the expression of the recombinant antigen in Hansenula polymorpha yeast cells. Currently, data on the immunogenicity of this vaccine in older adults are nonexistent. This study aimed to evaluate the immunogenicity of VrHB-IB in adults over 40 years of age. From May to October 2011, 235 rural settlers between 2 and 93 years of age from the State of Goias in Brazil were eligible for vaccination. Of these, 180 accepted the first dose of the vaccine and 106 (58.9%) completed the vaccination schedule. Multivariate analysis revealed that individuals ≥ 40 years of age responded significantly less well to vaccination than younger adults. Also, a greater proportion of male nonresponders was observed (versus women; P = 0.02). These results point to the need for better evaluation of the immunogenicity of VrHB-IB in older adults.
Author Notes
Authors' addresses: Karlla Antonieta Amorim Caetano, Raquel Silva Pinheiro, and Sheila Araujo Teles, Faculdade de Enfermagem, Universidade Federal de Goias, Goiania, Brazil, E-mails: karllacaetano@gmail.com, raquelsilva932@gmail.com, and sheila.fen@gmail.com. Nativa Helena Alves Del-Rios and Megmar Aparecida dos Santos Carneiro, Instituto de Patologia Tropical e Saúde Pública, Universidade Federal de Goias, Goiania, Brazil, E-mails: nativa_rios@yahoo.com.br and megmar242@gmail.com. Fabiana Perez Rodrigues Bergamaschi, Ciências da Saúde, Universidade Estadual do Mato Grosso do Sul, Dourados, Brazil, E-mail: fa.rodrigues@hotmail.com.
ProCite
RefWorks
Reference Manager
BibTeX
Zotero
EndNote
-
1.
Michel ML, Tiollais P, 2010. Hepatitis B vaccines: protective efficacy and therapeutic potential. Pathol Biol (Paris) 58: 288–295.
-
2.
Franco E, Bagnato B, Marino MG, Meleleo C, Serino L, Zaratti L, 2012. Hepatitis B: epidemiology and prevention in developing countries. World J Hepatol 4: 74–80.
-
3.
Zanetti AR, Van Damme P, Shouval D, 2008. The global impact of vaccination against hepatitis B: a historical overview. Vaccine 26: 6266–6273.
-
4.
Shouval D, Ilan Y, Adler R, Deepen R, Panet A, Even-Chen Z, Gorecki M, Gerlich WH, 1994. Improved immunogenicity in mice of a mammalian cell-derived recombinant hepatitis B vaccine containing pre-S and pre-S2 antigens as compared with conventional yeast-derived vaccines. Vaccine 12: 1453–1459.
-
5.
Martins RM, Bensabath G, Arraes LC, Oliveira MLA, Miguel JC, Barbosa GG, Camacho LAB, 2004. Multicenter study on the immunogenicity and safety of two recombinant vaccines against hepatitis B. Mem Inst Oswaldo Cruz 99: 865–871.
-
6.
Moraes JC, Luna EJA, Grimaldi RA, 2010. Imunogenicidade da vacina brasileira contra hepatite B em adultos. Rev Saude Publica 44: 353–359.
-
7.
Ministério da Saúde Brasil, 2015. Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis. Departamento de DST, Aids e Hepatites Virais, ed. Brasília (Brasil): Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais, 120.
-
8.
Souto FJD, 2016. Distribution of hepatitis B infection in Brazil: the epidemiological situation at the beginning of the 21st century. Rev Soc Bras Med Trop 49: 11–23.
-
9.
Ximenes RAA, Figueiredo GM, Cardoso MRA, Stein AT, Moreira RC, Coral G, Crespo D, Santos AA, Montarroyos UR, Braga MC, Pereira LMMB, 2015. Population-based multicentric survey of hepatitis B infection and risk factors in the north, south, and southeast regions of Brazil, 10–20 years after the beginning of vaccination. Am J Trop Med Hyg 93: 1341–1348.
-
10.
Vermeiren AP, Hoebe CJ, Dukers-Muijrers NH, 2013. High non-responsiveness of males and the elderly to standard hepatitis B vaccination among a large cohort of healthy employees. J Clin Virol 58: 262–264.
-
11.
Chathuranga LS, Noordeen F, Abeykoon AM, 2013. Immune response to hepatitis B vaccine in a group of health care workers in Sri Lanka. Int J Infect Dis 17: 1078–1079.
-
12.
Motta-Castro ARC, Gomes SA, Yoshida CFT, Miguel JC, Teles SA, Martins RMB, 2009. Compliance with and response to hepatitis B vaccination in remaining quilombo communities in central Brazil. Cad Saude Publica 25: 738–742.
-
13.
Klein SL, Marriott I, Fish EN, 2015. Sex-based differences in immune function and responses to vaccination. Trans R Soc Trop Med Hyg 109: 9–15.
-
14.
Gilbert CL, Klopfer SO, Martin JC, Schödel FP, Bhuyan PK, 2011. Safety and immunogenicity of a modified process hepatitis B vaccine in healthy adults ≥50 years. Hum Vaccin 7: 1336–1342.
-
15.
Kulkarni PS, Raut SK, Patki PS, Phadke MA, Jadhav SS, Kapre SV, Dhorje SP, Godse SR, 2006. Immunogenicity of a new, low-cost recombinant hepatitis B vaccine derived from Hansenula polymorpha in adults. Vaccine 24: 3457–3460.
-
16.
Meeren OVD, Crasta P, Cheuvart B, Ridder MD, 2015. Characterization of an age-response relationship to GSK's recombinant hepatitis B vaccine in healthy adults: an integrated analysis. Hum Vaccin Immunother 11: 1726–1729.
-
17.
Rosenberg C, Bovin NV, Bram LV, Flyvbjerg E, Erlandsen M, Vorup-Jensen T, Petersen E, 2013. Age is an important determinant in humoral and T cell responses to immunization with hepatitis B surface antigen. Hum Vaccin Immunother 9: 1466–1476.
-
18.
Vijayakumar V, Hari R, Parthiban R, Mehta J, Thyagarajan SP, 2004. Evaluation of immunogenicity and safety of Genevac B: a new recombinant hepatitis b vaccine in comparison with Engerix B and Shanvac B in healthy adults. Indian J Med Microbiol 22: 34–38.
-
19.
Ministério da Saúde Brasil, 2015. Protocolo Clínico e Diretrizes Terapêuticas para Atenção Integral às Pessoas com Infecções Sexualmente Transmissíveis. Departamento de DST, Aids e Hepatites Virais, ed. Brasília (Brasil): Ministério da Saúde, Secretaria de Vigilância em Saúde, Departamento de DST, Aids e Hepatites Virais, 120.
| Past two years | Past Year | Past 30 Days | |
|---|---|---|---|
| Abstract Views | 272 | 237 | 11 |
| Full Text Views | 466 | 9 | 0 |
| PDF Downloads | 151 | 6 | 0 |